Cidara Therapeutics, Inc. (CDTX)
BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
- Headquarters
- United States
- Employees
- 73
- Market Cap
- $7.0B
About Cidara Therapeutics, Inc.
Cidara Therapeutics Inc is developing immunotherapeutics designed to help improve the standard of care for patients facing serious diseases. Its clinical-stage asset is CD388, a DFC intended for influenza prophylaxis. The Company's portfolio comprises new approaches aimed at transforming existing treatment and prevention paradigms, including DFCs from its proprietary Cloudbreak platform targeting oncologic, viral and autoimmune diseases.
SentiSense also tracks daily options readings for Cidara Therapeutics, Inc.: IV rank, put/call percentile, 25-delta skew, open-interest walls, and unusually active contracts, each measured against the stock's own history. Sign in to view them.
Cidara Therapeutics, Inc. stock analysis, sentiment tracking, and market intelligence on SentiSense.